The burden of protozoan disease is not evenly distributed across the globe, and this asymmetry shapes nearly every aspect of how new therapies are discovered, tested, and eventually deployed. The parasites responsible for malaria, leishmaniasis, Chagas disease, and human African trypanosomiasis thrive in precisely those regions where health systems are weakest, diagnostic infrastructure is scarcest, and research funding is hardest to secure. This creates a self-reinforcing cycle: because these diseases primarily affect low-income populations, pharmaceutical companies have limited commercial incentives to invest in new drug development, and because investment is limited, the therapeutic arsenal remains anchored to compounds discovered decades ago. The editorial’s framing of quinoline and related N-heterocycles as lead structures must be understood against this backdrop. These scaffolds are attractive not only for their demonstrated biology but also because their synthetic accessibility and well-characterized pharmacology make them realistic candidates for development in resource-constrained settings, where elaborate manufacturing processes or expensive biological therapeutics would be impractical.

One of the most instructive themes running through the collected articles is the way structure-activity relationships in quinoline chemistry reveal mechanistic logic rather than arbitrary patterns. The observation that a substituted-aniline moiety at the 4-position of aminoquinolines enhances leishmanicidal potency relative to an alkylamine chain suggests that the aromatic amine contributes specific interactions with the parasite’s mitochondrial machinery that flexible aliphatic chains cannot replicate. Similarly, the finding that lipophilic alkenyl or aryl chains favor activity and selectivity when placed at the 2-, 3-, or 6-positions, while O- or N-substituents are preferred at the 8-position, points to distinct binding environments within the parasite cell that reward different physicochemical properties at different locations on the quinoline ring. This positional specificity is a hallmark of a scaffold engaged in meaningful target engagement rather than nonspecific membrane disruption, and it provides medicinal chemists with a rational map for optimization rather than a trial-and-error landscape.

The role of natural products in this optimization process deserves particular attention. The compilation of quinoline-based secondary metabolites active against Leishmania models demonstrates that evolution has already explored portions of quinoline chemical space that synthetic chemists might not otherwise prioritize. The predominance of 2-alkylquinolines among the isolated bioactive metabolites is especially telling, since the alkyl chain at this position appears to be a recurring motif that nature has validated across multiple producing organisms. When such a metabolite serves as the structural platform for synthetic analogues, as occurred with the 2-substituted quinoline derived from the natural 2-alkylquinoline lead, the process represents a form of biomimetic drug design in which the synthetic chemist refines and extends a molecular hypothesis that biology has already partially tested. This approach has historical precedent in antimalarial drug discovery, where quinine itself, a natural quinoline alkaloid, provided the template for generations of synthetic antimalarials.

The antimalarial articles in the collection illustrate two complementary strategies for modernizing the quinoline scaffold. The first strategy retains the classical mechanism of action, targeting β-hematin polymerization, but introduces modern functional groups such as ureas, carbamates, and thioureas to modulate potency and pharmacokinetics. The near-equivalence between the leading compound’s β-hematin inhibition and that of chloroquine, combined with strong in vivo performance in the Plasmodium berghei model and low hematotoxicity, suggests that the classical heme-polymerization target remains viable when the scaffold is appropriately decorated. This is significant because resistance to chloroquine, driven by mutations in parasite transporters that expel the drug from the digestive vacuole, has historically undermined this mechanism. New quinolines that overcome or circumvent these resistance mechanisms while preserving the heme-polymerization target would represent a meaningful advance, particularly for regions where chloroquine resistance is widespread.

The second antimalarial strategy departs from the classical mechanism entirely, targeting the parasite’s dihydrofolate reductase enzyme through quinoline-thiazolidinone hybrids. This approach demonstrates the versatility of the quinoline ring as a carrier of pharmacophoric elements rather than as the pharmacophore itself. The potent enzyme inhibition observed, with several compounds achieving inhibitory concentrations below two micromolar, indicates that the hybrid scaffold accommodates the binding requirements of the folate pathway enzyme while the quinoline portion contributes favorable physicochemical properties. The in vivo performance of the leading hybrid, reducing parasitemia substantially with extended animal survival, provides proof of concept that quinoline-based structures can succeed against targets unrelated to heme metabolism. This mechanistic diversification is strategically important because it reduces the risk that a single resistance mechanism could compromise an entire chemical class.

The hexahydroquinoline review adds a further dimension to this chemical space by examining partially saturated quinoline analogues. The distinction between the two hexahydroquinoline tautomeric forms, 1,4,5,6,7,8-hexahydroquinoline and 1,2,3,4,4a,5-hexahydroquinoline, reflects the conformational flexibility that partial saturation introduces. Unlike the planar aromatic quinoline, hexahydroquinolines adopt three-dimensional shapes that can engage biological targets through different interaction modes. The reported activity of 1,4,5,6,7,8-hexahydro-6-oxo-3-carboxylquinolines against Plasmodium falciparum, Leishmania species, Trypanosoma cruzi, and Toxoplasma gondii suggests that these scaffolds may interact with conserved parasite biology, possibly related to the parasite’s mitochondrial or metabolic functions, that is shared across multiple protozoan species. A scaffold with this breadth of activity could serve as a starting point for developing agents useful against several diseases simultaneously, an efficiency gain that would be particularly valuable given the limited resources available for antiprotozoal drug discovery.

The translational perspective offered in the collection raises questions that extend beyond chemistry into the broader architecture of drug development for neglected diseases. The observation that computational data and experimental findings remain insufficiently integrated reflects a persistent challenge in medicinal chemistry for neglected tropical diseases. Computational predictions of binding affinity, selectivity, and pharmacokinetic behavior are only as useful as the experimental systems available to validate them, and for many protozoan parasites, particularly the intracellular stages of T. cruzi and the liver stages of Plasmodium, robust and reproducible experimental models are technically demanding. Improving this integration requires not only better algorithms and more powerful computing but also standardized biological assays, open sharing of screening data, and collaborative networks that connect computational groups with parasitology laboratories. The editorial’s call for more robust strategies in this area is a recognition that the bottleneck in antiprotozoal drug discovery is often not the generation of candidate molecules but the reliable evaluation of their therapeutic potential.

The immunostimulatory dimension of 4-aminoquinoline activity against Leishmania adds a layer of complexity that distinguishes antiprotozoal drug design from antibacterial or antiviral approaches. Because Leishmania parasites reside within host macrophages, an effective drug must either kill the parasite directly within its intracellular niche or activate the host cell’s own antimicrobial machinery. The reported increase in proinflammatory cytokine and nitric oxide production by infected macrophages treated with 4-aminoquinolines suggests that these compounds operate through both mechanisms simultaneously. This dual action is potentially advantageous because it engages the host immune system in a way that is harder for the parasite to evade through genetic mutation alone. However, it also raises questions about the therapeutic window, since excessive immunostimulation could contribute to inflammatory pathology. Balancing direct parasiticidal activity with controlled immune activation is a design challenge specific to intracellular protozoan infections and one that the quinoline scaffold appears well positioned to address.

The mitochondrial mechanism proposed for 4-aminoquinolines, involving depolarization of the parasite’s mitochondrial membrane potential and subsequent apoptosis-like cell death, connects this chemical class to a broader family of mitochondria-targeted antiprotozoal strategies. Protozoan parasites possess single mitochondria with distinctive bioenergetic features that differ from those of mammalian cells, including alternative electron transport components and unique metabolic enzymes. These differences provide potential selectivity handles that medicinal chemists can exploit. The morphological changes observed in parasites treated with 4-aminoquinolines are consistent with a programmed cell death pathway, a phenomenon that has been increasingly recognized in protozoa and that offers a therapeutic endpoint distinct from the more commonly targeted parasite-specific enzymes or transporters.

Looking forward, the quinoline scaffold’s continued relevance to antiprotozoal drug discovery will depend on how successfully the insights from this collection are translated into optimized clinical candidates. The convergence of positional substitution logic, natural product validation, mechanistic diversity, and demonstrated in vivo efficacy across multiple protozoan models provides a foundation that is more comprehensive than what any single article could offer. The physicochemical parameters highlighted throughout the collection, particularly lipophilicity and acidity, will be critical determinants of whether laboratory potency survives the journey through absorption, distribution, metabolism, and excretion to reach therapeutically relevant concentrations at the site of infection. Compounds that are too lipophilic may suffer from poor solubility and nonspecific tissue accumulation, while those that are insufficiently lipophilic may fail to penetrate the intracellular niches where protozoan parasites reside. The quinoline ring, with its moderate aromatic character and tunable substitution pattern, occupies a favorable middle ground in this balance, which may partly explain its enduring success as a lead structure across multiple generations of antiprotozoal agents.

The collective message of this Research Topic is that the quinoline and related N-heterocycle scaffolds are not relics of a previous era of antiprotozoal chemotherapy but living platforms whose optimization potential remains far from exhausted. The seven articles gathered here demonstrate that new substitution patterns, new hybrid architectures, new partially saturated analogues, and new mechanistic hypotheses continue to emerge from this chemical family. For researchers working in medicinal chemistry, parasitology, and translational medicine, the collection offers both a summary of current achievements and a roadmap for future investigation, one in which rational design informed by structure-activity relationships, validated by biological experimentation, and guided by the practical constraints of the diseases being targeted can converge to produce the next generation of antiprotozoal therapies.

Subject of Research: …

Article Title: Editorial: Quinoline and N-heterocycle analogues as lead structures for the development of antiprotozoal agents

Article References: Romero, A. H., Benaim, G., Charris, J., & Cerecetto, H. (2026). Editorial: Quinoline and N-heterocycle analogues as lead structures for the development of antiprotozoal agents. Frontiers in Chemistry, 14, Article 2005043. https://doi.org/10.3389/fchem.2026.2005043

Image Credits: AI Generated

DOI: 10.3389/fchem.2026.2005043

Keywords: quinoline, antiprotozoal agents, leishmaniasis, malaria, Chagas disease, N-heterocycles, medicinal chemistry, drug discovery, 4-aminoquinolines, hexahydroquinoline, trypanosomiasis, neglected tropical diseases